Discovery of I-0436650, a potent and selective SHP2 allosteric inhibitor for the treatment of RAS driven solid tumors

被引：0

作者：

Puca, F. ^{[1
]}

Fodale, V. ^{[1
]}

Randazzo, P. ^{[2
]}

Fabbrini, D. ^{[2
]}

Missineo, A. ^{[1
]}

Bisbocci, M. ^{[3
]}

Esposito, S. ^{[4
]}

Nibbio, M. ^{[4
]}

Amaudrut, J. ^{[2
]}

Colaceci, F. ^{[5
]}

Sasso, R. ^{[5
]}

Scalabri, F. ^{[1
]}

Loponte, S. ^{[1
]}

Alli, C. ^{[3
]}

Pucci, V. ^{[4
]}

Montalbetti, C. ^{[2
]}

Di Fabio, R. ^{[2
]}

Petrocchi, A. ^{[2
]}

Carugo, A. ^{[1
]}

Toniatti, C. ^{[1
]}

机构：

[1] IRBM SpA, Biol, Rome, Italy

[2] IRBM SpA, Small Mol R&D, Rome, Italy

[3] IRBM SpA, Translat Res, Rome, Italy

[4] IRBM SpA, Expt Pharmacol, Rome, Italy

[5] IRBM SpA, Vivo Pharmacol, Rome, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S26 / S26

页数：1

共 50 条

[1] Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors
Williams, Bret
Taylor, Alexander
Orozco, Olivia
Owen, Christopher
Kelley, Elizabeth
Lescarbeau, Andre
Shortsleeves, Kelley
Kipp, Randy
Nguyen, Vy
Brophy, Erin
Wilbur, Jeremy
Tang, Yong
Lanzetta, David
Waters, Nigel
Smith, Sherri
Giordanetto, Fabrizio
Maragakis, Paul
Greismann, Jack
Willmore, Lindsay
Therrien, Eric
Xiao, Yang
Evangelista, Marie
Gerosa, Luca
Lin, Eva
Merchant, Mark
Arrazate, Alfonso
Chan, Emily
Larrocha, Pablo Saenz-Lopez
Chun, Stefan
Hunsaker, Thomas
Deshmukh, Gauri
Bowman, Christine M.
Shaw, David E.
Murcko, Mark
Padval, Mahesh
Walters, W. Patrick
Watters, James
Bergstrom, Donald A.
CANCER RESEARCH, 2022, 82 (12)
[2] Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor
Puca, Francesca
Fabbrini, Danilo
Ciammaichella, Alina
Missineo, Antonino
Bisbocci, Monica
Nibbio, Martina
Di Marco, Annalise
Apicella, Claudia
Colaceci, Fabrizio
Sasso, Romina
Natale, Daniela
Scalabri, Francesco
Alli, Cristina
Pucci, Vincenzo
Montalbetti, Christian
Petrocchi, Alessia
Carugo, Alessandro
Toniatti, Carlo
CANCER RESEARCH, 2024, 84 (06)
[3] Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment
Luo, Ruixiang
Fu, Weitao
Shao, Jingjing
Ma, Lin
Shuai, Sujuan
Xu, Ying
Jiang, Zheng
Ye, Zenghui
Zheng, Lulu
Zheng, Lei
Yu, Jie
Zhang, Yawen
Yin, Lina
Tu, Linglan
Lv, Xinting
Li, Jie
Liang, Guang
Chen, Lingfeng
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 253
[4] Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment
Ma, Cunbo
Kang, Di
Gao, Panliang
Zhang, Wei
Wu, Xinping
Xu, Zilong
Han, Huifeng
Zhang, Lei
Cai, Yang
Wang, Yanping
Wang, Yinxiang
Long, Wei
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (16) : 13534 - 13549
[5] Discovery of ETS-001, a highly potent allosteric SHP2 inhibitor to treat RTK/RAS-driven cancers.
Xia, Xi
Du, Lin
Hao Zhuge
Zheng, Qiangang
Cui, Wenqi
Zhu, Jidong
Li, Guo
CANCER RESEARCH, 2021, 81 (13)
[6] Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors
Petrocchi, Alessia
Grillo, Alessandro
Ferrante, Luca
Randazzo, Pietro
Prandi, Adolfo
De Matteo, Marilenia
Iaccarino, Costanza
Bisbocci, Monica
Cellucci, Antonella
Alli, Cristina
Nibbio, Martina
Pucci, Vincenzo
Amaudrut, Jerome
Montalbetti, Christian
Toniatti, Carlo
Di Fabio, Romano
ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (05): : 645 - 651
[7] Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
Fortanet, Jorge Garcia
Chen, Christine Hiu-Tung
Chen, Ying-Nan P.
Chen, Zhouliang
Deng, Zhan
Firestone, Brant
Fekkes, Peter
Fodor, Michelle
Fortin, Pascal D.
Fridrich, Cary
Grunenfelder, Denise
Ho, Samuel
Kang, Zhao B.
Karki, Rajesh
Kato, Mitsunori
Keen, Nick
LaBonte, Laura R.
Larrow, Jay
Lenoir, Francois
Liu, Gang
Liu, Shumei
Lombardo, Franco
Majumdar, Dyuti
Meyer, Matthew J.
Palermo, Mark
Perez, Lawrence
Pu, Minying
Ramsey, Timothy
Sellers, William R.
Shultz, Michael D.
Stams, Travis
Towler, Christopher
Wang, Ping
Williams, Sarah L.
Zhang, Ji-Hu
LaMarche, Matthew J.
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (17) : 7773 - 7782
[8] Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor
Tang, Kai
Wang, Shu
Feng, Siqi
Yang, Xinyu
Guo, Yueyang
Ren, Xiangli
Bai, Linyue
Yu, Bin
Liu, Hong-Min
Song, Yihui
ACTA PHARMACEUTICA SINICA B, 2024, 14 (08) : 3624 - 3642
[9] Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors
Torrente, Esther
Fodale, Valentina
Ciammaichella, Alina
Ferrigno, Federica
Ontoria, Jesus M.
Ponzi, Simona
Rossetti, Ilaria
Sferrazza, Alessio
Amaudrut, Jerome
Missineo, Antonino
Esposito, Simone
Palombo, Simone
Nibbio, Martina
Cerretani, Mauro
Bisbocci, Monica
Cellucci, Antonella
di Marco, Annalise
Alli, Cristina
Pucci, Vincenzo
Toniatti, Carlo
Petrocchi, Alessia
ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (02): : 156 - 162
[10] An allosteric inhibitor of SHP2 effectively targets PDGFRα-driven glioblastoma
Tannous, Bakhos A.
Badr, Christian E.
NEURO-ONCOLOGY, 2019, 21 (11) : 1348 - 1349

← 1 2 3 4 5 →